Posted by Michael Wonder on 13 Aug 2020
For company behind coronavirus drug, sharp questions over pricing, potentially cheaper option
13 August 2020 - Gilead says it's testing remdesivir alternative amid questions from watchdog.
After initial excitement about the discovery of a promising treatment for some coronavirus patients, executives with Gilead Sciences are now facing harsh criticism over the initial business decisions they’ve made in the midst of a pandemic.
In recent days, state leaders and a government watchdog group have levelled complaints against the company for the price point it set for its antiviral drug remdesivir, a promising treatment shown to diminish recovery time in hospitalised coronavirus patients, and for allegedly not more quickly pursing a potentially cheaper alternative. Gilead holds exclusive manufacturing rights for remdesivir.
